Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study
Universitaire Ziekenhuizen KU Leuven
2,000 participants
Jul 1, 2020
OBSERVATIONAL
Conditions
Summary
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
Eligibility
Inclusion Criteria1
- all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent
Exclusion Criteria1
- age under 18 years
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04579471